Mirum Pharmaceuticals, Inc. (MIRM) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Foster City, CA, United States. Der aktuelle CEO ist Christopher Peetz.
MIRM hat IPO-Datum 2019-07-18, 334 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $4.86B.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing novel therapies for rare and orphan diseases affecting the liver and bile system. The company's lead product candidate, LIVMARLI, is an investigational oral medication designed to treat progressive familial intrahepatic cholestasis, Alagille syndrome, and biliary atresia. Mirum also develops Volixibat for the treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018 and headquartered in Foster City, California, Mirum focuses on addressing critical unmet needs in hepatobiliary diseases.
